Injectable methods for non-surgical fat reduction, such as mesotherapy or Lipodissolve1 have been researched for over two decades. After initial enthusiasm, these fat-reduction therapies lost popularity due to lack of controlled studies and unwanted side effects.2 Recently, however, the availability of new formulations, most of them based on deoxycholic acid, has produced an increase in their demand, particularly following the US Food and Drug Administration’s (FDA) approval of one of them in 2015, ATX-101, for reduction of submental fat.3
At the end of the 1980s, an Italian doctor began to use a mesotherapy preparation containing phosphatidylcholine (PC) for the infiltration of xanthelasmas. He achieved satisfactory results and presented his method at the 5th International Mesotherapy Congress in Paris in 1988.4 In 1995, Brazilian dermatologist Dr Patricia Rittes treated her lower eye…
